The table below lists the % of gram-negative organisms that tested susceptible to each listed drug or combination in 2019-2021, excluding Stenotrophomonas maltophilia isolates. The values incorporate the frequency with which the various organisms were isolated as well as their sensitivity to the drug; more commonly isolated organisms contribute more to the overall susceptibility results. Results are based on standard methodology. Next update planned with 2022-2024 data.
| Population | Number of Isolates | Ceftriaxone | Ceftazidime | Cefepime | Pip/tazo | Meropenem |
| All inpatient/ED isolates | 860 | 72% (84%)* | 89% | 91% (94%)# | 92% | 97% |
| ICN | 115 | 81% (86%)*, ** | 90% | 94% (97%)# | 90% | 100% |
| PICU & CICU | 224 | 59% (81%)* | 85% | 88% (93%)# | 89% | 95% |
| non-ICU | 523 | 76% (85%)* | 90% | 91% (93%)# | 93% | 97% |
* Value in parenthesis is susceptibility if Pseudomonas and Acinetobacter are excluded
** Gentamicin susceptibility among ICN Gram-negative isolates is 85% (92% if Pseudomonas and Acinetobacter are excluded)
# Value in parentheses represents the percentage of isolates both fully susceptible and susceptible-dose depedent to cefepime. Susceptible-dose depedent isolates are Enterobacteriaceae with MIC 4 to 8 micrograms/mL for which a cefepime dose of 50 mg/kg/dose iv q8h with maximum 2g/dose, as routinely recommended per BCH Pediatric Antimicrobial Dosing Guidelines, anticipated to be active.
Gram Negative Combinations by Location
The table below details the percent susceptibility of inpatient gram-negative isolates to single agents and to the combination of antimicrobials indicated (number to the right of the arrow). Data are from 2019-2021.
MER = meropenem; TOB = tobramycin; PIPTAZ = piperacillin/tazobactam; CFPM = cefepime; CIP = ciprofloxacin
| Population | Number of Isolates |
PIPTAZ --> PIPTAZ + CIP |
PIPTAZ --> PIPTAZ + TOB |
CFPM# --> CFPM + CIP |
CFPM# --> CFPM + TOB |
MER --> MER + CIP |
MER --> MER + TOB |
| All inpatient/ED isolates | 860 | 92% --> 99% | 92% --> 100% | 94% --> 96% | 94% --> 97% | 97% --> 99% | 97% --> 99% |
| ICN | 115 | N/A | 90% --> 100% | N/A | 97% --> 98% | N/A | 100% --> 100% |
| PICU & CICU | 222 | 89% --> 99% | 89% --> 100% | 93% --> 96% | 93% --> 96% | 95% --> 98% | 95% --> 99% |
| non-ICU | 532 | 93% --> 99% | 93% --> 99% | 93% --> 95% | 93% --> 97% | 97% --> 99% | 97% --> 99% |
# Numbers for cefepime combination threapy analysis are based on the percentage of isolates both fully susceptible and susceptible-dose depedent to cefepime.